Table 4 Clinical trials based on CIKs and genetically modified T cells under study for the treatment of HCC
Regimen | Population | Design | Estimated/Actual enrollment | NCT number |
|---|---|---|---|---|
CIKs mono-therapy for HCC | ||||
 CIKs | • Hepatocellular carcinoma | • Phase 3 clinical trial • CIK treatments within 3 months after liver resection | 200 | NCT00769106 |
 CIKs | • Hepatocellular carcinoma • Renal cell carcinoma • Lung cancer | • Phase 1 clinical trial • CIK treatments following radical resection | 40 | NCT01914263 |
 CIKs | • Hepatocellular carcinoma | • Phase 3 clinical trial • CIK treatments following radical resection | 200 | NCT01749865 |
 DC-CIKs | • Hepatocellular carcinoma | • Phase 2 clinical trial • Dendritic and CIKs used to treat HCC patients who got CR or PR after complete resection/ TACE | 100 | NCT01821482 |
CIKs in combination with other therapies for HCC | ||||
 CIKs+ anti PD-1 antibodies | • Hepatocellular carcinoma • Renal cell carcinoma • Bladder cancer • Colorectal cancer • Non-small-cell lung cancer • Breast cancer | • Phase 2 clinical trial • Combination therapy | 50 | NCT02886897 |
 CIKs+ TACE | • Hepatocellular carcinoma • Digestive system neoplasms | • Phase 3 clinical trial • Combination therapy | 60 | NCT02487017 |
 CIKs+ RFA | • Hepatocellular carcinoma | • Phase 3 clinical trial • RFA + Highly-purified CTL vs. RFA Alone for Recurrent HCC after partial hepatectomy | 210 | NCT02678013 |
CAR-T trials for HCC treatment | ||||
 Anti-GPC3 CAR-T | • Hepatocellular carcinoma (GPC3 + advanced HCC) | • Phase 1/2 clinical trial | 20 | NCT03084380 |
 Anti-GPC3 CAR-T | • Hepatocellular carcinoma (GPC3 + advanced HCC) | • Phase 1/2 clinical trial | 60 | NCT02723942 |
 Autologous anti-AFP (ET1402L1)-CAR-T | • AFP expressing hepatocellular carcinoma | • Phase 1 clinical trial • The second generation CAR-T treatment | 18 | NCT03349255 |
 Anti-GPC3 CAR-T | • Advanced hepatocellular carcinoma | • Phase 1 clinical trial | 13 | NCT02395250 |
 Anti-GPC3 CAR-T | • Advanced hepatocellular carcinoma | • Phase 1 clinical trial | 30 | NCT03198546 |
 TAI-GPC3-CAR-T | • Hepatocellular carcinoma | • Phase 1/2 clinical trial • GPC3-CAR-Ttreatment mediated by the method of transcatheter arterial infusion (TAI) | 30 | NCT02715362 |
 Anti-GPC3 CAR-T | • Advanced hepatocellular carcinoma | • Phase 1/2 clinical trial • GPC3-CAR-Ttreatment by intratumor injection | 10 | NCT03130712 |
 Anti-Mucin1 (MUC1) CAR-T | • Hepatocellular carcinoma • Non-small cell lung cancer • Pancreatic carcinoma • Triple-negative invasive breast carcinoma | • Phase 1/2 clinical trial • Patients with MUC1+ advanced refractory solid tumor | 20 | NCT02587689 |
 Anti-GPC3 CAR-T | • Relapsed or refractory hepatocellular carcinoma | • A single arm, open-label pilot study • GPC3+ hepatocellular carcinoma | 20 | NCT03146234 |
 Anti-EpCAM CAR-T | • Colon cancer • Esophageal carcinoma • Pancreatic cancer • Prostate cancer • Gastric cancer • Hepatic carcinoma | • Phase 1/2 clinical trial • Targeting patients with EpCAM+ cancer | 60 | NCT03013712 |
 CAR-T targeting TAAs | • Hepatocellular carcinoma • Pancreatic cancer • Colorectal cancer | • Phase 1/2 clinical trial • CAR-T targets: GPC3 for hepatocellular carcinoma • Mesothelin for pancreatic cancer • CEA for colorectal cancer | 20 | NCT02959151 |